United States

JCR Pharmaceuticals Co Ltd (4552.T)

4552.T on Tokyo Stock Exchange

2:00am EDT
Change (% chg)

¥-14 (-0.57%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

JCR Pharmaceuticals to initiate development of JR-162
Thursday, 23 Feb 2017 01:40am EST 

JCR Pharmaceuticals Co Ltd <4552.T> : Says it plans to initiate development of a new drug candidate, JR-162 .Says JR-162 is a blood-brain barrier (BBB)-penetrating acid alpha-glucosidase (GAA) for treating Pompe disease which uses J-Brain Cargo, JCR’s BBB penetration technology.  Full Article

PeptiDream signs collaborative research agreement with JCR Pharmaceuticals
Monday, 22 Feb 2016 01:00am EST 

PeptiDream Inc:Says signed collaborative research agreement with JCR Pharmaceuticals for development of special cyclic peptide for target protein.  Full Article

JCR Pharmaceuticals and MEDIPAL HOLDINGS launch new product TEMCELL
Tuesday, 16 Feb 2016 01:00am EST 

JCR Pharmaceuticals Co Ltd:The company and MEDIPAL HOLDINGS CORPORATION announced that TEMCELL® HS Inj. (human (allogeneic) bone marrow derived mesenchymal stem cells) which was approved for marketing in September last year, will become available on Feb. 24.Says will be distributed utilizing the ultra-low cold chain system developed jointly with MEDIPAL.  Full Article

JCR Pharmaceuticals raises consolidated mid-year outlook for FY 2016
Friday, 28 Aug 2015 03:00am EDT 

JCR Pharmaceuticals Co Ltd:Says the company increased the consolidated mid-year outlook for revenue to 8,700 mln yen from 8,500 mln yen, for the fiscal year ending March 2016.Operating profit forecast increased to 1,330 mln yen from 1,000 mln yen.Ordinary profit forecast increased to 1,500 mln yen from 1,160 mln yen.Net profit forecast increased to 1,070 mln yen from 800 mln yen.Earnings per share increased to 33.56 yen from 25.13 yen.Comments the improvement in sale of core products is the main reason for the forecast.  Full Article

JCR Pharmaceuticals announces feasibility testing contract with Eisai
Tuesday, 21 Jul 2015 02:00am EDT 

JCR Pharmaceuticals Co Ltd:Says the company signed a feasibility testing contract with Eisai Co Ltd on July 21, regarding on discovering therapeutic medication through J-Brain Cargo, a technology owned by the company.  Full Article

Sumitomo Dainippon Pharma and JCR Pharmaceuticals conclude a feasibility study agreement on application of the blood-brain barrier penetration technology in psychiatry and neurology area
Wednesday, 17 Jun 2015 03:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd and JCR Pharmaceuticals Co Ltd:JCR Pharmaceuticals (“JCR”) and Sumitomo Dainippon Pharma executed on June 17 a feasibility study agreement.Under which they will study the feasibility of applying JCR’s proprietary blood-brain barrier penetration technology “J-Brain Cargo” to discovery of new treatment in the psychiatry and neurology area.Under the terms of the agreement, JCR and Sumitomo Dainippon Pharma will perform collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Sumitomo Dainippon Pharma’s choice.With a view to creating innovative pharmaceutical products in psychiatry and neurology area, where high unmet medical needs exist.  Full Article

Shin Nippon Biomedical Laboratories announces business alliance with JCR Pharmaceuticals
Monday, 1 Jun 2015 03:00am EDT 

Shin Nippon Biomedical Laboratories Ltd:Signed business alliance with JCR Pharmaceuticals on June 1.Says the business alliance regarding commissioned business of J-Brain Cargo technology of JCR Pharmaceuticals.  Full Article

More From Around the Web